Table 2 Univariate analysis for the clinical characteristics of subjects with a favorable or unfavorable outcome

Sex, n (%)

0.515

 Female

18(38.3)

17(32.1)

 Male

29(61.7)

36(67.9)

Age, yr, mean (SD)

55.28(13.67)

61.40(12.22)

< 0.05*

BMI(Kg/m2), median (IQR)

24.22(22.49–26.45)

24.00(23.43–26.10)

0.966

Hypertension, n (%)

21(44.7)

34(64.2)

< 0.05*

Diabetes, n (%)

1(2.1)

11(20.8)

< 0.01*

Hematoma location, n (%)

0.248

 Basal ganglia

17(36.2)

28(52.8)

 Lobar

9(19.1)

5(9.4)

 Thalamus

12(25.5)

14(26.4)

 Cerebellum

5(10.6)

1(1.8)

 Brainstem

1(2.1)

2(3.8)

 Ventricle

3(6.4)

3(5.7)

Into the ventricle, n (%)

17(36.2)

28(52.8)

0.095

Final ICH volume(ml), n (%)

< 0.001*

 < 30

34(72.3)

18(34)

 ≥ 30

13(27.7)

35(66)

Hydrocephalus, n (%)

6(12.8)

10(18.9)

0.406

GCS, median (IQR)

11(9–14)

6(5–8)

< 0.0001*

Time from symptom onset to MIS (hours), mean (SD)

4.091(4.302)

4.235(2.547)

0.176

Infection while in hospital, n (%)

10(21.3)

17(32.1)

0.225

Routine examination of CSF

 WBC(n), median (IQR)

3040(160–9190)

4280(225-18540)

0.213

 RBC(n), median (IQR)

8(4-120)

80(6-420)

0.073

Biochemical reactions of CSF

 PRO(g/L), median (IQR)

0.78(0.44–1.44)

1.64(0.6-2.645)

< 0.01*

 GLU (mmol/L), median (IQR)

3.47(3.080–4.88)

4.605(3.3-6.323)

< 0.05*

 CL (mmol/L), median (IQR)

121.8(117.1-125.6)

122.9(118.1-131.5)

0.134